24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Risk of Falls Up With Mild, Moderate Diabetic RetinopathyFirst-Line Metformin Use for DM Up; Sulfonylurea Use DownPoor Prognosis for Diabetic Foot SoresER- Breast CA Risk Up for African-Americans With T2DMIn 2007-2014, Glycemic Control Plateaued in Diabetes PatientsDiabetes May Be Driving High Rates of Breast Cancer in Black WomenLeisure Time Exercise Linked to Reduced Mortality in T1DMAHA: Sudden Cardiac Death Risk Up for Young With DiabetesYounger People With Diabetes Have 7 Times Greater Risk of Sudden Heart DeathRisk of End-Stage Renal Disease Low With Type 1 DiabetesDrop in Incidence of End-Stage Renal Disease Due to DiabetesHealth Tip: Choosing Smarter FoodsLifestyle Changes Successfully Reduce Incidence of DiabetesNovel Method Developed for Estimating Prevalence of DiabetesNovel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DMKidney Failure Declining Among U.S. Diabetics: CDCACE Inhibitor, Statin No Benefit for T1DM, High Albumin ExcretionMagnesium, T2DM Link Seen in Poor-Carbohydrate-Quality DietRetinal Sensitivity Linked to Cognitive Status in T2DMKidney Damage Seen in Most Patients With Long-Lasting T1DArterial Stiffness Linked to Incidence of DiabetesUndiagnosed Diabetes Accounts for Small Portion of DiabetesNew Clinical Practice Guideline for Management of T2DMDiabetes Tied to Worse Outcomes in Heart Failure PatientsStatins May Raise Odds of T2DM in Those at High RiskFinancial Incentives Up Teen Glucose Monitoring AdherenceFewer Diabetes Cases Being MissedSudden Death Most Common CV Death in T2DM/ASCVDDiabetes Ups Risk of MACE in Acute Coronary SyndromesLifestyle, Metformin Interventions Have Variable EffectsHealth Tip: Best Grains And Starchy Veggies for DiabeticsGlycemic Control Up With Oral Semaglutide in Type 2 DiabetesCommercial Weight Management Program May Help Prevent T2DDiabetes Pill Might Replace Injection to Control Blood SugarNew Screening Tool Can Identify Diabetic RetinopathyRisk Conferred by T2D Modified by HbA1c in Heart FailureNo Causal Link Between Plasma Lipids, Diabetic RetinopathyBetter Glycemic Control With Insulin Pump for Youth With T1DPump May Beat Shots for Type 1 DiabetesWhere There's Type 1 Diabetes, Celiac Disease May FollowFlu Shot Key for People With DiabetesMaking Halloween a Treat for Kids With DiabetesPay for Performance Cuts Mortality in Diabetes PatientsAddition of DPP4i to AGI Reduces HbA1c in T2DMRare Tumor May Point the Way to Diabetes TreatmentInsulinomas May Hold Key to Diabetes Drug DevelopmentFDA: New Glucose Monitoring System Eliminates Finger PricksFDA Approves New Continuous Glucose Monitor for DiabetesInsulin Dose Not Tied to Cardiovascular OutcomesDiabetes Treatment Failure May Actually Be Nonadherence
Links
Related Topics

Medical Disorders

Early Glycemic Control With Metformin Cuts CVD Events


HealthDay News
Updated: Apr 21st 2017

new article illustration

FRIDAY, April 21, 2017 (HealthDay News) -- For patients with type 2 diabetes who initiate metformin, early achievement of low hemoglobin A1c (HbA1c) is associated with a reduction in the subsequent risk of cardiovascular events or death, according to a study published online April 12 in Diabetes Care.

Elisabeth Svensson, Ph.D., from Aarhus University Hospital in Denmark, and colleagues conducted a population-based study involving 24,572 metformin initiators with HbA1c tests in Northern Denmark from 2000 to 2012 (median follow-up, 2.6 years). Patients were classified by HbA1c achieved at six months after metformin initiation and by the magnitude of change in HbA1c from the pretreatment base.

The researchers found that, compared with a target HbA1c of <6.5 percent, the risk of a combined outcome event (acute myocardial infarction, stroke, or death) increased gradually with increasing levels of HbA1c achieved (adjusted hazard ratios, 1.18 for 6.5 to 6.99 percent; 1.23 for 7.0 to 7.49 percent; 1.34 for 7.5 to 7.99 percent, and 1.59 for ≥8 percent). Outcome was also predicted by a large absolute HbA1c reduction from baseline (adjusted hazard ratio, 0.80 for Δ = −4, compared with no change [Δ = 0]).

"A large initial HbA1c reduction and achievement of low HbA1c levels within six months after metformin initiation are associated with a lower risk of cardiovascular events and death in patients with type 2 diabetes," the authors write.

Several authors disclosed financial ties to Novo Nordisk, which partially funded the study.

Abstract
Full Text